| lamivudine / Generic mfg. |
| Completed | 4 | 36 | RoW | Tenofovir, Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV) | Kirby Institute, The University of New South Wales, Gilead Sciences | HIV Infection, Hepatitis B Coinfection | 01/07 | 01/07 | | |
NCT00120354: Long-Term Lamivudine Therapy for Chronic Hepatitis B |
|
|
| Completed | 4 | 50 | US | Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Hepatitis B, Chronic | | 03/07 | | |
NCT00230477: Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT |
|
|
| Completed | 4 | 19 | US | Hepsera, Hepsera and lamivudine | University of Washington, Gilead Sciences, GlaxoSmithKline | Hepatitis B | | 08/07 | | |
NCT00460850: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. |
|
|
| Terminated | 4 | 60 | RoW | peginterferon alfa-2a (40KD) [PEGASYS] | Hoffmann-La Roche | Hepatitis B, Chronic | | 06/08 | | |
NCT00393484: A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection |
|
|
| Completed | 4 | 122 | RoW | Entecavir, Baraclude, BMS-200475, Lamivudine Placebo, Lamivudine, Entecavir Placebo | Bristol-Myers Squibb | Chronic Hepatitis B | 01/09 | 09/13 | | |
NCT00625560: Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA |
|
|
| Completed | 4 | 72 | RoW | Entecavir, Baraclude 1.0mg, Lamivudine, Zeffix 100mg | Yonsei University, Pusan National University Hospital | Hepatitis B, Chronic | 11/09 | 11/10 | | |
NCT00798460: Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients |
|
|
| Terminated | 4 | 30 | RoW | adefovir, Hepsera, clevudine, Levovir, lamivudine, Zeffix | Inje University, Bukwang Pharmaceutical | Chronic Hepatitis B | 06/10 | 11/10 | | |
NCT00637663: Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA |
|
|
| Completed | 4 | 72 | RoW | Entecavir, Baraclude 0.5mg, Lamivudine, Zeffix 100mg QD | Pusan National University Hospital, Yonsei University | Hepatitis B, Chronic | 11/10 | 11/10 | | |
NCT00625339: Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA |
|
|
| Completed | 4 | 72 | RoW | Entecavir, Baraclude 0.5mg, Lamivudine, Zeffix 100mg QD | Yonsei University, Pusan National University Hospital | Hepatitis B, Chronic | 11/10 | 11/10 | | |
NCT00531167: Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B |
|
|
| Completed | 4 | 219 | RoW | combination of lamivudine+adefovir vs entecavir, Zeffix, Hepsera, Baraclude | Korea University, GlaxoSmithKline | Chronic Hepatitis B | 04/11 | 10/12 | | |
NCT01788371: Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus |
|
|
| Completed | 4 | 700 | RoW | Telbivudine, Lamivudine | Hua Zhang, Icahn School of Medicine at Mount Sinai | Hepatitis B Infection, Chronic Infection, Viremia | 07/12 | 07/13 | | |
CAESAR, NCT01023217: Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir |
|
|
| Completed | 4 | 90 | RoW | Adefovir, Adefovir dipivoxil (Hepsera), Entecavir, Entecavir (Baraclude), Lamivudine, Lamivudine (Zeffix) | Asan Medical Center | Hepatitis B, Chronic | 07/12 | 09/12 | | |
NCT00558493: Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients |
|
|
| Completed | 4 | 100 | RoW | Clevudine | Bukwang Pharmaceutical | Chronic Hepatitis B | | | | |
NCT00986778: Entecavir Plus Adefovir in Lamivudine-Resistant Patients |
|
|
| Withdrawn | 4 | 0 | RoW | Lamivudine, Heptotin, Entecavir, Baraclude, Adefovir, Hepsera | Bristol-Myers Squibb | Hepatitis B, Chronic | 12/12 | 06/14 | | |
| Completed | 4 | 366 | RoW | lamivudine, lamivudine, adefovir | Nanfang Hospital of Southern Medical University, Major Science and Technology Special Project of China Eleventh Five-year, GlaxoSmithKline | Compensated Chronic Hepatitis B | 02/13 | 05/13 | | |
NCT02202473: Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects |
|
|
| Completed | 4 | 192 | RoW | Lamivudine, Lamivudine+Oxymatrine Capsules | Southeast University, China, Cttq | Chronic Hepatitis B | 02/14 | | | |
SASL28, NCT01005238: Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine |
|
|
| Terminated | 4 | 27 | Europe | Lamivudine, Telbivudine | University Hospital, Basel, Switzerland | Hepatitis, Chronic | 12/14 | | | |
NCT01627223: Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation |
|
|
| Terminated | 4 | 17 | RoW | Lamivudine, Zeffix®, Entecavir, Baraclude® | Taichung Veterans General Hospital, GlaxoSmithKline | Chronic Hepatitis B | 04/16 | 04/16 | | |
